title: SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies.
abstract: BACKGROUND
  Patients with high-risk, relapsed or refractory Hodgkin lymphoma, those with systemic anaplastic large-cell lymphoma, and those with primary cutaneous CD30-positive disorders are in need of novel therapies. CD30, a common marker in these malignancies, is a reasonable immunologic target given its restricted expression in normal states. SGN-30 is a chimeric antibody targeting CD30.
  
  
  OBJECTIVE
  Review of data regarding SGN-30, including structure, mechanism of action, pharmacokinetics, efficacy in different patient groups, safety, and tolerability.
  
  
  METHODS
  The medical literature and available abstracts regarding SGN-30 are reviewed.
  
  
  CONCLUSIONS
  SGN-30 may be efficacious through multiple mechanisms of action. The most efficacious dose has yet to be determined. Given the long drug half-life, short infusions may be administered every 2 - 3 weeks. The highest response rate was seen in patients with primary cutaneous CD30-positive lymphoproliferative disease and encouraging results were seen in patients with relapsed or refractory systemic anaplastic large-cell lymphoma. Most responses in Hodgkin lymphoma were stable disease. Despite a majority of patients having had stem cell transplantation, the drug was well tolerated. There are in vivo and in vitro data that SGN-30 may be synergistic with chemotherapy.
authors.affiliation: Clinical Professor of Medicine, Geffen School of Medicine at UCLA, Director, UCLA Lymphoma Program, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA. lpinterbrown@mednet.ucla.edu
authors.forename: Lauren C
authors.initials: LC
authors.lastname: Pinter-Brown
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004361:Drug Tolerance; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D017730:Ki-1 Antigen / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D017730:Ki-1 Antigen; C504717:SGN-30 monoclonal antibody